18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT07102056
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • 18F-AlF-NOTA-Octreotide PET-CT or PET-MR — DIAGNOSTIC_TEST
    18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Study Details

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Key Dates

Start date
Jan 1, 2026
Status verified
Dec 2024
Primary completion
Jun 3, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
152 participants (estimated)

Primary Outcome Measure

Diagnostic efficacy [ Time Frame: through study completion, an average of 1.5 year ]

Central Contacts

Related Studies